Lack of anti-TNF drugs levels in fistula tissue – a reason for nonresponse in Crohn’s perianal fistulating disease?

Conclusion Absence of detection of the anti-TNF drugs in fistula tissue raises the question on the role of tissue penetrance of anti-TNF drugs in response to therapy. Further work is required in a larger number of patients to validate the findings observed and investigate if any correlation exists between tissue and serum levels of anti-TNF and clinical outcome. Summary Predicting response in Crohn’s fistula patients on biologic therapy is difficult with no reliable biomarkers. This pilot study uses targeted proteomics to investigate the potential role of tissue drug levels in acting as a biomarker of treatment response.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original articles: Gastroenterology Source Type: research